Cargando…

Tigecycline activity against metallo-β-lactamase-producing bacteria

BACKGOUND: Treatment of serious life-threatening multi-drug-resistant organisms poses a serious problem due to the limited therapeutic options. Tigecycline has been recently marketed as a broad-spectrum antibiotic with activity against both gram-positive and gram-negative bacteria. Even though many...

Descripción completa

Detalles Bibliográficos
Autores principales: Kumar, Simit, Bandyopadhyay, Maitreyi, Mondal, Soma, Pal, Nupur, Ghosh, Tapashi, Bandyopadhyay, Manas, Banerjee, Parthajit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3841483/
https://www.ncbi.nlm.nih.gov/pubmed/24327967
http://dx.doi.org/10.4103/2231-0770.120500
_version_ 1782292782256226304
author Kumar, Simit
Bandyopadhyay, Maitreyi
Mondal, Soma
Pal, Nupur
Ghosh, Tapashi
Bandyopadhyay, Manas
Banerjee, Parthajit
author_facet Kumar, Simit
Bandyopadhyay, Maitreyi
Mondal, Soma
Pal, Nupur
Ghosh, Tapashi
Bandyopadhyay, Manas
Banerjee, Parthajit
author_sort Kumar, Simit
collection PubMed
description BACKGOUND: Treatment of serious life-threatening multi-drug-resistant organisms poses a serious problem due to the limited therapeutic options. Tigecycline has been recently marketed as a broad-spectrum antibiotic with activity against both gram-positive and gram-negative bacteria. Even though many studies have demonstrated the activity of tigecycline against ESBL-producing Enterobacteriaceae, its activity is not well-defined against micro-organisms producing metallo-β-lactamases (MBLs), as there are only a few reports and the number of isolates tested is limited. AIMS: The aim of the present study was to evaluate the activity of tigecycline against MBL-producing bacterial isolates. MATERIALS AND METHODS: The isolates were tested for MBL production by (i) combined-disk test, (ii) double disc synergy test (DDST), (iii) susceptibility to aztreonam (30 μg) disk. Minimum inhibitory concentration to tigecycline was determined according to agar dilution method as per Clinical Laboratory Standards Institute (CLSI) guidelines. Disc diffusion susceptibility testing was also performed for all these isolates using tigecycline (15 μg) discs. RESULTS: Among the total 308 isolates included in the study, 99 were found to be MBL producers. MBL production was observed mostly in isolates from pus samples (40.47%) followed by urine (27.4%) and blood (13.09%). MBL production was observed in E. coli (41.48%), K. pneumoniae (26.67%), Proteus mirabilis (27.78%), Citrobacter spp. (41.67%), Enterobacter spp. (25.08%), and Acinetobacter spp. (27.27%). The result showed that tigecycline activity was unaffected by MBL production and it was showed almost 100% activity against all MBL-producing isolates, with most of the isolates exhibiting an MIC ranging from 0.25-8 μg/ml, except 2 MBL-producing E. coli isolates who had an MIC of 8 μg/ml. CONCLUSION: To conclude, tigecycline was found to be highly effective against MBL-producing Enterobacteriaceae and acinetobacter isolates, but the presence of resistance among organisms, even before the mass usage of the drug, warrants the need of its usage as a reserve drug. The study also found that the interpretative criteria for the disc diffusion method, recommended by the FDA, correlates well with the MIC detection methods. So, the microbiology laboratories might use the relatively easier method of disc diffusion, as compared to the comparatively tedious method of MIC determination.
format Online
Article
Text
id pubmed-3841483
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-38414832013-12-10 Tigecycline activity against metallo-β-lactamase-producing bacteria Kumar, Simit Bandyopadhyay, Maitreyi Mondal, Soma Pal, Nupur Ghosh, Tapashi Bandyopadhyay, Manas Banerjee, Parthajit Avicenna J Med Original Article BACKGOUND: Treatment of serious life-threatening multi-drug-resistant organisms poses a serious problem due to the limited therapeutic options. Tigecycline has been recently marketed as a broad-spectrum antibiotic with activity against both gram-positive and gram-negative bacteria. Even though many studies have demonstrated the activity of tigecycline against ESBL-producing Enterobacteriaceae, its activity is not well-defined against micro-organisms producing metallo-β-lactamases (MBLs), as there are only a few reports and the number of isolates tested is limited. AIMS: The aim of the present study was to evaluate the activity of tigecycline against MBL-producing bacterial isolates. MATERIALS AND METHODS: The isolates were tested for MBL production by (i) combined-disk test, (ii) double disc synergy test (DDST), (iii) susceptibility to aztreonam (30 μg) disk. Minimum inhibitory concentration to tigecycline was determined according to agar dilution method as per Clinical Laboratory Standards Institute (CLSI) guidelines. Disc diffusion susceptibility testing was also performed for all these isolates using tigecycline (15 μg) discs. RESULTS: Among the total 308 isolates included in the study, 99 were found to be MBL producers. MBL production was observed mostly in isolates from pus samples (40.47%) followed by urine (27.4%) and blood (13.09%). MBL production was observed in E. coli (41.48%), K. pneumoniae (26.67%), Proteus mirabilis (27.78%), Citrobacter spp. (41.67%), Enterobacter spp. (25.08%), and Acinetobacter spp. (27.27%). The result showed that tigecycline activity was unaffected by MBL production and it was showed almost 100% activity against all MBL-producing isolates, with most of the isolates exhibiting an MIC ranging from 0.25-8 μg/ml, except 2 MBL-producing E. coli isolates who had an MIC of 8 μg/ml. CONCLUSION: To conclude, tigecycline was found to be highly effective against MBL-producing Enterobacteriaceae and acinetobacter isolates, but the presence of resistance among organisms, even before the mass usage of the drug, warrants the need of its usage as a reserve drug. The study also found that the interpretative criteria for the disc diffusion method, recommended by the FDA, correlates well with the MIC detection methods. So, the microbiology laboratories might use the relatively easier method of disc diffusion, as compared to the comparatively tedious method of MIC determination. Medknow Publications & Media Pvt Ltd 2013 /pmc/articles/PMC3841483/ /pubmed/24327967 http://dx.doi.org/10.4103/2231-0770.120500 Text en Copyright: © Avicenna Journal of Medicine http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Kumar, Simit
Bandyopadhyay, Maitreyi
Mondal, Soma
Pal, Nupur
Ghosh, Tapashi
Bandyopadhyay, Manas
Banerjee, Parthajit
Tigecycline activity against metallo-β-lactamase-producing bacteria
title Tigecycline activity against metallo-β-lactamase-producing bacteria
title_full Tigecycline activity against metallo-β-lactamase-producing bacteria
title_fullStr Tigecycline activity against metallo-β-lactamase-producing bacteria
title_full_unstemmed Tigecycline activity against metallo-β-lactamase-producing bacteria
title_short Tigecycline activity against metallo-β-lactamase-producing bacteria
title_sort tigecycline activity against metallo-β-lactamase-producing bacteria
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3841483/
https://www.ncbi.nlm.nih.gov/pubmed/24327967
http://dx.doi.org/10.4103/2231-0770.120500
work_keys_str_mv AT kumarsimit tigecyclineactivityagainstmetalloblactamaseproducingbacteria
AT bandyopadhyaymaitreyi tigecyclineactivityagainstmetalloblactamaseproducingbacteria
AT mondalsoma tigecyclineactivityagainstmetalloblactamaseproducingbacteria
AT palnupur tigecyclineactivityagainstmetalloblactamaseproducingbacteria
AT ghoshtapashi tigecyclineactivityagainstmetalloblactamaseproducingbacteria
AT bandyopadhyaymanas tigecyclineactivityagainstmetalloblactamaseproducingbacteria
AT banerjeeparthajit tigecyclineactivityagainstmetalloblactamaseproducingbacteria